CPRX Catalyst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CPRX

Price (delayed)

$16.49

Market cap

$1.74B

P/E Ratio

20.61

Dividend/share

N/A

EPS

$0.8

Enterprise value

$1.45B

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK ...

Highlights
The EPS has soared by 111% year-on-year and by 23% since the previous quarter
Catalyst Pharmaceuticals's net income has surged by 110% YoY and by 24% QoQ
Catalyst Pharmaceuticals's quick ratio has decreased by 27% YoY and by 10% QoQ
The stock's P/E is 10% more than its last 4 quarters average of 18.8
Sector: Healthcare
Industry: Biotechnology
Website: http://www.catalystpharma.com
Peers: BMRN SRPT JNJ ACOR

Key stats

What are the main financial stats of CPRX
Market
Shares outstanding
105.65M
Market cap
$1.74B
Enterprise value
$1.45B
Valuations
Price to earnings (P/E)
20.61
Price to book (P/B)
5.71
Price to sales (P/S)
7.96
EV/EBIT
13.82
EV/EBITDA
13.63
EV/Sales
6.76
Earnings
Revenue
$214.2M
EBIT
$104.72M
EBITDA
$106.21M
Free cash flow
$116.02M
Per share
EPS
$0.8
Free cash flow per share
$1.12
Book value per share
$2.89
Revenue per share
$2.07
TBVPS
$3.32
Balance sheet
Total assets
$375.63M
Total liabilities
$75.21M
Debt
$3.56M
Equity
$300.42M
Working capital
$263.21M
Liquidity
Debt to equity
0.01
Current ratio
5.57
Quick ratio
5.36
Net debt/EBITDA
-2.78
Margins
EBITDA margin
49.6%
Gross margin
83.9%
Net margin
38.8%
Operating margin
47.5%
Efficiency
Return on assets
27.2%
Return on equity
32.2%
Return on invested capital
518.6%
Return on capital employed
32.9%
Return on sales
48.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
-0.24%
1 week
14.99%
1 month
7.22%
1 year
98.91%
YTD
-11.34%
QTD
-11.34%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$214.2M
Gross profit
$179.81M
Operating income
$101.84M
Net income
$83.08M
Gross margin
83.9%
Net margin
38.8%
Catalyst Pharmaceuticals's net income has surged by 110% YoY and by 24% QoQ
The company's operating income has surged by 94% YoY and by 22% QoQ
The revenue has soared by 52% YoY and by 12% QoQ
Catalyst Pharmaceuticals's gross profit has surged by 51% YoY and by 12% QoQ

Growth

What is Catalyst Pharmaceuticals's growth rate over time

Valuation

What is Catalyst Pharmaceuticals stock price valuation
P/E
20.61
P/B
5.71
P/S
7.96
EV/EBIT
13.82
EV/EBITDA
13.63
EV/Sales
6.76
The EPS has soared by 111% year-on-year and by 23% since the previous quarter
The stock's P/E is 10% more than its last 4 quarters average of 18.8
Catalyst Pharmaceuticals's equity has increased by 45% YoY and by 11% QoQ
The stock's price to book (P/B) is 30% more than its 5-year quarterly average of 4.4 and 27% more than its last 4 quarters average of 4.5
The price to sales (P/S) is 73% lower than the 5-year quarterly average of 30.1 but 25% higher than the last 4 quarters average of 6.4
The revenue has soared by 52% YoY and by 12% QoQ

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC has soared by 104% since the previous quarter
The ROE has soared by 58% YoY and by 13% from the previous quarter
CPRX's return on assets is up by 49% year-on-year and by 10% since the previous quarter
The ROS has increased by 31% year-on-year and by 11% since the previous quarter

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
The total liabilities has soared by 143% YoY and by 19% QoQ
The total assets has soared by 58% year-on-year and by 13% since the previous quarter
Catalyst Pharmaceuticals's debt is 99% lower than its equity
CPRX's debt to equity has dropped by 50% year-on-year
Catalyst Pharmaceuticals's equity has increased by 45% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.